Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11

Mehrling, Thomas; Soltis, Daniel; The Antibodies Editorial Office,

doi:10.3390/antib7030032

Open AccessCorrection

Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11

by

Thomas Mehrling

¹,

Daniel Soltis

² and

The Antibodies Editorial Office

^3,*

¹

Mundipharma EDO GmbH, Basel CH-4020, Switzerland

²

Consultant, Cleveland Heights, OH 441188, USA

³

MDPI, St. Alban-Anlage 66, 4052 Basel, Switzerland

^*

Author to whom correspondence should be addressed.

Antibodies 2018, 7(3), 32; https://doi.org/10.3390/antib7030032

Submission received: 21 August 2018 / Accepted: 22 August 2018 / Published: 27 August 2018

Download Versions Notes

The Conflict of Interest section of the published paper [1] has been updated as follows:

“Thomas Mehrling is an employee of Mundipharma EDO, which is currently developing the ADCs EDO-B278 and EDO-B776. Daniel Soltis is a consultant to Mundipharma EDO.”

The manuscript will be updated and the original will remain online on the article webpage.

Reference

Mehrling, T.; Soltis, D. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11. [Google Scholar] [CrossRef]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Share and Cite

MDPI and ACS Style

Mehrling, T.; Soltis, D.; The Antibodies Editorial Office. Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11. Antibodies 2018, 7, 32. https://doi.org/10.3390/antib7030032

AMA Style

Mehrling T, Soltis D, The Antibodies Editorial Office. Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11. Antibodies. 2018; 7(3):32. https://doi.org/10.3390/antib7030032

Chicago/Turabian Style

Mehrling, Thomas, Daniel Soltis, and The Antibodies Editorial Office. 2018. "Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11" Antibodies 7, no. 3: 32. https://doi.org/10.3390/antib7030032

APA Style

Mehrling, T., Soltis, D., & The Antibodies Editorial Office. (2018). Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11. Antibodies, 7(3), 32. https://doi.org/10.3390/antib7030032

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11

Reference

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI